Picture of Quest Diagnostics logo

DGX — Quest Diagnostics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Quest Diagnostics Q3 revenue beats; raises 2026 revenue forecast

Quest Diagnostics Q3 revenue beats; raises 2026 revenue forecast


Overview

  • U.S. diagnostic lab's Q3 revenue grew 10% yr/yr, beating analyst expectations

  • Adjusted EPS for Q3 rose 15.4% yr/yr, beating analyst expectations

  • Company raised full-year 2026 revenue and EPS guidance


Outlook

  • Quest Diagnostics raises 2026 revenue guidance to $12.065 bln-$12.105 bln

  • Company now expects 2026 reported diluted EPS of $10.21-$10.31

  • Company sees 2026 adjusted diluted EPS between $11.25 and $11.35


Result Drivers

  • CHANNEL GROWTH - Co said strong performance across physician, hospital and consumer channels drove Q3 results

  • ORGANIC GROWTH - Co attributed robust organic revenue growth to expanding clinical care needs of aging population and increased focus on prevention and wellness

  • AUTOMATION AND AI - Productivity gains from automation and AI contributed to Q3 performance, per CEO Jim Davis


Company press release: ID:nPn8Wfps2a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$3.10 bln

$3.05 bln (14 Analysts)

Q3 Adjusted EPS

Beat

$3

$2.86 (15 Analysts)

Q3 EPS

$2.78

Q3 Net Income

$312 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Quest Diagnostics Inc is $251.00, about 5.1% above its October 21 closing price of $238.93

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago


Reuters Recommended Reads

  • Oct 21 - Thermo Fisher Q3 revenue, adj profit beat estimates after new product launches

  • Oct 21 - Danaher Q3 adjusted EPS beats, FY guidance raised

  • Oct 21 - Elevance Health Q3 adjusted EPS beats estimates, raises outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Quest Diagnostics

See all news